Last reviewed · How we verify
AGG-523
At a glance
| Generic name | AGG-523 |
|---|---|
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement (PHASE1)
- Study Evaluating AGG-523 in Subjects With Osteoarthritis (PHASE1)
- A Study of the Safety, Tolerability, and Pharmacokinetics of AGG-523 in Healthy Japanese Males (PHASE1)
- Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGG-523 CI brief — competitive landscape report
- AGG-523 updates RSS · CI watch RSS